AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 22 min read$GILD

O'Day Daniel Patrick sold $138K of GILD

O'Day Daniel Patrick (Chairman & CEO) sold 1,038 shares of GILEAD SCIENCES, INC. (GILD) at $132.97 ($0.14M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'Day Daniel Patrick
Published Jun 2, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GILD
Neutral
medium confidence
Mentioned
$GILD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GILDNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider liquidity/compensation but does not introduce new company fundamentals or guidance.

02

Market read

A routine 10b5-1 insider sale; likely limited trading impact absent other catalysts.

03

What to watch

Traders may over-weight small insider sales; the key is whether there are multiple consecutive insider transactions or changes in plan behavior, which are not provided here.

Relevance 6/10Novelty 3/10Timing: Filed today; sale executed 2026-06-01

Background

SEC Form 4 discloses insider transactions; this one is an open-market sale by Gilead’s Chairman & CEO under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$GILDNeutralMedium confidence
Context

Gilead CEO/Chairman O'Day sold $138K of GILD shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 open-market sale, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying fundamental catalyst disclosed.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector/regulatory catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may be mechanically scheduled and not reflect bearish expectations—treat as noise unless paired with other negative signals.

Key entities

  • issuer
    Gilead Sciences, Inc.

    Subject of the insider sale disclosure (Form 4).

  • insider
    O'Day Daniel Patrick

    Chairman & CEO who sold 1,038 shares at ~$132.97 on 2026-06-01 under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$GILDMed

Weekly HIV Pill Held Viral Suppression as Well as Daily Therapy in Phase 3 Trial

Phase 3 ISLEND-1 results in the New England Journal of Medicine found a once-weekly tablet of islatravir 2 mg plus lenacapavir 300 mg was noninferior to once-daily bictegravir, emtricitabine, and tenofovir alafenamide for maintaining HIV viral suppression at 48 weeks in 607 adults already suppressed for at least 6 months. None on weekly therapy had HIV-1 RNA ≥50 copies/mL vs 0.3% on daily. Serious adverse events were 5.3% vs 4.6%.

medicaldaily.com7 min
AUG 7
$GILDMedAI 8/10

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences (GILD) reported Q2 2026 non-GAAP loss per share of $6.75 and revenue of $7.8B, both above consensus. Management raised 2026 product sales guidance excluding Veklury to $29.8B-$30.1B and lifted HIV sales growth outlook to 9%-10%. CEO cited HIV and PrEP strength, Trodelvy growth, and ongoing anito-cel launch prep.

zacks.com6 min
AUG 6
$MRKMed

MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data

Merck & Co (MSD) and Gilead Sciences ended the Phase III KEYNOTE-D46/EVOKE-03 trial in frontline PD-L1-expressing NSCLC after an external data monitoring committee projected the Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) would not significantly improve overall survival versus Keytruda alone. Trodelvy-Keytruda showed nonsignificant PFS benefit and no new safety issues. Trodelvy Q2 2026 sales rose 26% to $457m.

yahoo.com3 min
AUG 5
$GILDMed

GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure

Gilead Sciences (GILD) reported Q2 CY2026 revenue of $7.80 billion, up 10.2% year over year, and a non-GAAP loss of $6.75 per share. Full-year revenue guidance was $30.25 billion at the midpoint, 0.6% below analysts’ estimates. Management cited HIV franchise strength, including Biktarvy and PrEP, plus Trodelvy growth, while noting margin pressure from acquisition-related R&D costs.

stockstory.org4 min